A new electrical stimulation therapy for spinal muscle atrophy (SMA) has shown promise in reactivating motor neurons and ...

The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...

Liver issues, including a buildup of fat in the liver, occur before the onset of neuromuscular disease, per a study in a mouse model of SMA.

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral ...

In a small human trial in SMA patients neurostimulation sessions improved motoneuron function, reduced fatigue, and improved leg muscle strength and walking.

BACKGROUND: Spinal Muscular Atrophy (SMA) is a group of genetic disorders characterized by the degeneration of motor neurons in the spinal cord and brainstem, leading to muscle weakness and atrophy.

A genetic neuromuscular disorder that affects motor neurons in the spinal cord causing progressive muscle degeneration ... type of SMA. A genetic condition caused by a mutation in the SMN 1 ...

Spinal muscular atrophy (SMA ... irreversible loss of motor neurons. SMA affects approximately one in 10,000 live births worldwide. The loss of motor neurons affects muscle functions, like ...

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

Biogen has announced that the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have started reviewing a higher dose regimen of its spinal muscular atrophy ... motor neuron ...